PBH Prestige Consumer Healthcare Inc

Prestige Brands Holdings, Inc. Appoints Christine Sacco as New Chief Financial Officer

Prestige Brands Holdings, Inc. (NYSE-PBH), a leading marketer of over-the-counter healthcare products, today announced the appointment of Christine “Chris” Sacco to the position of Chief Financial Officer for the Company.

Ms. Sacco is a seasoned public company chief financial officer, bringing more than 19 years of experience in corporate finance, treasury, investor relations, strategic planning, operations and mergers and acquisitions focused on consumer products and specialty pharma companies. She joins Prestige following eight years at Boulder Brands, Inc. where she served as Chief Financial Officer for the last four years. Prior to Boulder, for five years she held positions of increasing financial responsibility with Alpharma, Inc., a global specialty pharma company, where she last held the position of Vice President, Treasurer. Ms. Sacco holds a BS from St. Thomas Aquinas College and is a Certified Public Accountant.

In making the announcement, Ron Lombardi, CEO, commented, “We are very pleased to have Chris join the Prestige team. She has an extensive financial background focusing on relevant industries, and her insight and experience will strengthen our management team and contribute to the growth and expansion of our brands.”

“I look forward to building upon the Company’s impressive history of growth and brand building,” Ms. Sacco said. “Prestige is a growing organization with an excellent business model and a proven track record of successful acquisitions and organic growth. I am confident I can contribute to the Company’s future growth, profitability and shareholder value,” she said.

About Prestige Brands Holdings, Inc.

The Company markets and distributes brand name over-the-counter healthcare and household cleaning products throughout the U.S. and Canada, Australia and in certain other international markets. The Company’s brands include Monistat® women’s health products, Nix® lice treatment, DenTek® oral care products, Chloraseptic® sore throat treatments, Clear Eyes® eye care products, Compound W® wart treatments, The Doctor's® NightGuard® dental protector, Little Remedies® pediatric products, Efferdent® denture care products, Luden's® throat drops, Dramamine® motion sickness treatment, BC® and Goody's® pain relievers, Beano® gas prevention, Debrox® earwax remover, and Gaviscon® antacid in Canada. Visit the Company's website at www.prestigebrands.com.

EN
12/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prestige Consumer Healthcare Inc

 PRESS RELEASE

UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 ...

UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  P...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue a...

Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Con...

 PRESS RELEASE

Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and...

Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in th...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results...

Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook Revenue of $290.3 million in Q3, up 2.7% versus prior yearDiluted EPS of $1.22 in Q3 increased approximately 15% versus prior yearReduced leverage to 2.5x in Q3, driven by strong profitability and cash flowRaising full-year fiscal 2025 earnings outlook TARRYTOWN, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024. “We are pleased with our strong t...

 PRESS RELEASE

Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earni...

Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earnings Results Date and ICR Conference Presentation TARRYTOWN, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 third quarter earnings release on Thursday, February 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To parti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch